A novel network analysis tool to identify relationships between disease states and risks for red blood cell alloimmunization

Vox Sanguinis

Volumn 112, Issue 5, 2017, Pages 469-472

  Celli, R ^a   Schulz, W ^a   Hendrickson, J E ^a   Tormey, C A ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

alloimmunization; immunohaematology; RBC antibodies

Indexed keywords

ALLOANTIBODY; ERYTHROCYTE ANTIBODY;

AGED; ALLOIMMUNIZATION; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; BLOOD TRANSFUSION; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; ERYTHROCYTE; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; ALLOGRAFT; BLOOD; IMMUNOLOGY; RISK ASSESSMENT; RISK FACTOR;

AGED; ALLOGRAFTS; ERYTHROCYTE TRANSFUSION; ERYTHROCYTES; HUMANS; ISOANTIBODIES; MALE; RISK ASSESSMENT; RISK FACTORS;

EID: 85017160190     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/vox.12515     Document Type: Article

References (11)

1. Higgins JM, Sloan SR: Stochastic modeling of human RBC alloimmunization: evidence for a distinct population of immunologic responders. Blood 2008; 112:2546–2553
2. Gehrie EA, Tormey CA: The influence of clinical and biological factors on transfusion-associated non-ABO antigen alloimmunization: responders, hyper-responders, and non-responders. Transfus Med Hemother 2014; 41:420–429
3. Chou ST, Fasano RM: Management of patients with sickle cell disease using transfusion therapy: guidelines and complications. Hematol Oncol Clin North Am 2016; 30:591–608
4. Hendrickson JE, Tormey CA: Red blood cell antibodies in hematology/oncology patients: interpretation of immunohematologic tests and clinical significance of detected antibodies. Hematol Oncol Clin North Am 2016; 30:635–651
5. Matteocci A, Pierelli L: Red blood cell alloimmunization in sickle cell disease and in thalassaemia: current status, future perspectives and potential role of molecular typing. Vox Sang 2014; 106:197–208
6. Evers D, van der Bom JG, Tijmensen J, et al.: Red cell alloimmunisation in patients with different types of infections. Br J Haematol 2016; 175:956–966
7. Divo MJ, Casanova C, Marin JM, et al.: Chronic obstructive pulmonary disease comorbidities network. Eur Respir J 2015; 46:640–650
8. Bastian M, Heymann S, Jacomy M. Gephi: an open source software for exploring and manipulating networks. Available at: http://www.gephi.org [Last accessed 29 November 2016]
9. Sanz C, Nomdedeu M, Belkaid M, et al.: Red blood cell alloimmunization in transfused patients with myelodysplastic syndrome or chronic myelomonocytic leukemia. Transfusion 2013; 53:710–715
10. Hendrickson JE, Eisenbarth SC, Tormey CA: Red blood cell alloimmunization: new findings at the bench and new recommendations for the bedside. Curr Opin Hematol 2016; 23:543–549
11. Tormey CA, Fisk J, Stack G: Red blood cell alloantibody frequency, specificity, and properties in a population of male military veterans. Transfusion 2008; 48:2069–2076